Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum

被引:48
作者
Gonzalez-Aseguinolaza, G [1 ]
Taladriz, S [1 ]
Marquet, A [1 ]
Larraga, V [1 ]
机构
[1] Spanish Res Council, Ctr Invest Biol, Dept Struct & Funct Prot, Madrid 28006, Spain
来源
EUROPEAN JOURNAL OF BIOCHEMISTRY | 1999年 / 259卷 / 03期
关键词
binding sequences; cell localization; gene cloning; Leishmania antigen; peptide libraries;
D O I
10.1046/j.1432-1327.1999.00122.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The p36/LACK antigen from Leishmania, an analogue of the receptor for activated protein kinase C (PKC), induces high levels of protection against parasite infection in the BALB/c mouse model. This protection is more than twice as high as that elicited by major parasite antigens such as soluble Leishmania antigen or the main surface protease gp63. We have cloned and purified p36/LACK from Leishmania infantum, the causative agent of visceral leishmaniasis in Europe. This protein belongs to the large family of WD 40 repeat proteins confined to eukaryotes and involved in numerous regulatory functions. Differential solubilization and immunofluorescence experiments indicate that p36/LACK is present close to the kinetoplast disc in the cell cytoplasm, probably bound to multiprotein complexes but not to membrane structures. These complexes probably also include cytoplasm PKC isoforms. The use of a genetically-encoded peptide library indicates that p36/LACK binds sequences present in several proteins involved in DNA replication and RNA synthesis. The recognition and binding sequences present in vacuolar proteins and at the beta-chain of major histocompatability complex (MHC) class II suggest the involvement of this regulatory protein in the early mechanisms triggering the protective immune response of the host against the parasite infection.
引用
收藏
页码:909 / 916
页数:8
相关论文
共 38 条
[31]   THE PRESENCE OF INTERLEUKIN-4 DURING INVITRO PRIMING DETERMINES THE LYMPHOKINE-PRODUCING POTENTIAL OF CD4+ T-CELLS FROM T-CELL RECEPTOR TRANSGENIC MICE [J].
SEDER, RA ;
PAUL, WE ;
DAVIS, MM ;
FAZEKAS DE ST GROTH, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (04) :1091-1098
[32]   Selective down-regulation of Th2 immune responses following treatment with antigen-coupled splenocytes [J].
Soldera, S ;
McSorley, SJ ;
Glaichenhaus, N .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (04) :848-854
[33]  
Soong L, 1997, J IMMUNOL, V158, P5374
[34]   DEVELOPMENT OF A SAFE LIVE LEISHMANIA VACCINE LINE BY GENE REPLACEMENT [J].
TITUS, RG ;
GUEIROSFILHO, FJ ;
DEFREITAS, LAR ;
BEVERLEY, SM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (22) :10267-10271
[35]  
Titus Richard G., 1992, V18, P99
[36]   THE ROLE OF INTERLEUKIN-12 IN THE IMMUNE-RESPONSE, DISEASE AND THERAPY [J].
TRINCHIERI, G ;
SCOTT, P .
IMMUNOLOGY TODAY, 1994, 15 (10) :460-463
[37]   Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans [J].
Valadon, P ;
Nussbaum, G ;
Boyd, LF ;
Margulies, DH ;
Scharff, MD .
JOURNAL OF MOLECULAR BIOLOGY, 1996, 261 (01) :11-22
[38]   HYDROGEN PEROXIDE-MEDIATED TOXICITY FOR LEISHMANIA-DONOVANI CHAGASI PROMASTIGOTES - ROLE OF HYDROXYL RADICAL AND PROTECTION BY HEAT-SHOCK [J].
ZARLEY, JH ;
BRITIGAN, BE ;
WILSON, ME .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (05) :1511-1521